The Goldman Consensus statement on depression in multiple sclerosis. Mult Scler 2005 Jun;11(3):328-37
Date
06/17/2005Pubmed ID
15957516DOI
10.1191/1352458505ms1162oaScopus ID
2-s2.0-20144384545 (requires institutional sign-in at Scopus site) 260 CitationsAbstract
BACKGROUND: In January 2002 the New York City Chapter of the National Multiple Sclerosis Society convened a panel of experts to review the issue of depressive affective disorders associated with multiple sclerosis (MS). This Consensus Conference was supported by a grant from the Goldman family of New York City.
RESULTS: The panel reviewed summaries of current epidemiologic, neurobiologic, and therapeutic studies having to do with depressive disorders among MS patient populations. Depressive disorders occur at high rates among patients with MS, and there is reason to believe that the immunopathology of the disease is involved in the clinical expression of affective disorders. The depressive syndromes of MS have a major, negative impact on quality of life for MS sufferers, but are treatable. At the present time, most MS patients with depression do not receive adequate recognition and treatment.
CONCLUSIONS: The Goldman Consensus Conference Study Group provides recommendations for improved screening, diagnosis, and clinical management for depressive affective disorders among patients suffering from MS.
Author List
Goldman Consensus GroupMESH terms used to index this publication - Major topics in bold
Depressive DisorderHumans
Multiple Sclerosis
Quality of Life
Risk Factors
Suicide
